Allen Loyd V
International Journal of Pharmaceutical Compounding.
Int J Pharm Compd. 2020 May-Jun;24(3):215-220.
Intravenous admixture compounding requires knowledge of stability, compatibility, and incompatibility issues related to the complete composition and formulation. In evaluating an intravenous admixture, one is not just concerned with the active ingredients but also with all the excipients. Both active pharmaceutical ingredients and excipients used in the formulations of commercially available products may vary among manufacturers and can influence drug compatibility and stability. Clinical pharmaceutics includes the study and application of pharmaceutics to clinical compounding situations to aid in the evaluation of each intravenous admixture. A critical aspect of successful intravenous admixture preparation is the prevention or minimization of particulate matter in the finished product. This article discusses the source, method of prevention, and detection of particulates in intravenous admixtures.
静脉药物混合配制需要了解与完整成分和制剂相关的稳定性、相容性和不相容性问题。在评估静脉药物混合制剂时，人们不仅关注活性成分，还关注所有辅料。市售产品制剂中使用的活性药物成分和辅料在不同制造商之间可能会有所不同，并且会影响药物的相容性和稳定性。临床药剂学包括将药剂学研究和应用于临床配制情况，以协助评估每种静脉药物混合制剂。成功制备静脉药物混合制剂的一个关键方面是预防或尽量减少成品中的颗粒物。本文讨论了静脉药物混合制剂中颗粒物的来源、预防方法和检测方法。
